Higher doses of treprostinil significantly delayed time to first pulmonary arterial hypertension-related or all-cause hospitalization.
Tadalafil, a phosphodiesterase 5 (PDE5) inhibitor, is indicated to treat pulmonary arterial hypertension to improve exercise ability.
FREEDOM-EV was an international, multicenter, randomized, double-blind, placebo-controlled trial (N=690) that randomized patients to 3 daily doses of Orenitram or placebo.
The sNDA is accompanied by results from the MERIT-1 trial, a Phase 2 randomized, placebo-controlled, double-blind study which assessed the efficacy, safety and tolerability of macitentan 10mg in 80 patients with inoperable CTEPH.
At 90 days, the prevalence of venous thromboembolism varied from 0.3 to 1.37% for all patients and from 0.75 to 3.86% for hospitalized patients.
In both yoga groups there was an increase in brachial artery flow-mediated dilation (P<0.05). In the time-control group there were no significant changes in any outcome variables.
The new device, TD-300/A, features a more ergonomic design with a single-button operation, an intuitive user interface to adjust breath counts, an internal, rechargeable battery, and a color graphical display that guides patients through the inhalation process and shows the time since last treatment.
Studies have shown that concomitant administration with gemfibrozil doubled exposure to selexipag and increased exposure to the active metabolite by approximately 11-fold.
Trevyent contain treprostinil, a vasodilatory prostacyclin analogue. It works primarily through vasodilation of pulmonary and systemic arterial vascular beds, and inhibition of platelet aggregation.
The mean and median pulmonary complications score was 1.8 and 1.7, respectively, for the intensive recruitment strategy group, compared with 2.1 and 2.0, respectively, for the moderate strategy group.
The team reviewed the latest research behind popular food trends to create an evidence-based prescription to provide clinicians with a quick guide to relay to patients in a clinical setting.
For patients with hemodynamically stable pulmonary embolism (PE), outpatient management is associated with a lower rate of adverse events, according to research published online January 20 in the Journal of Thrombosis and Haemostasis.
Reviva announced that the Food and Drug Administration (FDA) has granted Orphan Drug Designation for RP5063, its lead development product for the treatment of pulmonary arterial hypertension (PAH).
A new study published in Anesthesiology has found that exposing red blood cells to the gas nitric oxide may reduce pulmonary hypertension associated with transfusion of red blood cells.
While treatment with continuous positive airway pressure (CPAP) reduces sleep apnea symptoms, it does not lower users' long-term odds for cardiovascular events, according to a study published online in the New England Journal of Medicine.
The use of inferior vena caval filters (IVCFs) for pulmonary embolism (PE) increased from 1999 through 2010, according to research published in the March 8 issue of the Journal of the American College of Cardiology.
Ambulatory pulmonary artery (PA) pressure-guided management of heart failure patients is more effective in reducing heart failure hospitalizations than management of patient clinical signs/symptoms alone, according to a study published online February 10 in JACC: Heart Failure.
Inhibition of mammalian target of rapamycin (mTOR) by rapamycin restores corticosteroid sensitivity in patients with chronic obstructive pulmonary disease (COPD), according to a study published in the American Journal of Respiratory
For patients with type 2 diabetes, there is no association between hospitalization for heart failure and treatment with dipeptidyl peptidase-4 inhibitors (DPP-4is) versus sulfonylureas (SUs) or treatment with saxagliptin versus sitagliptin.
The Food and Drug Administration (FDA) has approved Uptravi (selexipag; Actelion) tablets for the treatment of adults with pulmonary arterial hypertension (PAH).
The Food and Drug Administration (FDA) has granted Orphan Drug designation to ubenimex (Eiger) for the treatment of pulmonary arterial hypertension (PAH).
Gilead Sciences announced that the Food and Drug Administration (FDA) has approved Letairis (ambrisentan) in combination with tadalafil for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1).
Exercise has a positive effect on several measures of heart function as well as overall quality of life for patients with pulmonary hypertension, according to research published recently in Circulation: Heart Failure.
Gilead Sciences announced positive results from the AMBITION study, a Phase 3/4 trial of first-line combination therapy with Letairis (ambrisentan) and tadalafil in patients with WHO/NYHA functional class II and III pulmonary arterial hypertension (PAH).
The six-minute walk (6MW) stress echocardiography test could be prognostic for development of pulmonary hypertension (PH) in connective tissue disease (CTD).
The Food and Drug Administration (FDA) has issued a warning that pulmonary hypertension has been reported in infants and newborns treated with Proglycem (diazoxide; Teva) for low blood glucose.